BR112015002526B1 - Derivado do (2r,3r)-éster do ácido 3-hidróxi-2-metil-4 [1,2,4]triazol-1-il-3-fenil-butírico, mistura de diastereoisômeros do referido éster e seu processo de fabricação - Google Patents

Derivado do (2r,3r)-éster do ácido 3-hidróxi-2-metil-4 [1,2,4]triazol-1-il-3-fenil-butírico, mistura de diastereoisômeros do referido éster e seu processo de fabricação Download PDF

Info

Publication number
BR112015002526B1
BR112015002526B1 BR112015002526-9A BR112015002526A BR112015002526B1 BR 112015002526 B1 BR112015002526 B1 BR 112015002526B1 BR 112015002526 A BR112015002526 A BR 112015002526A BR 112015002526 B1 BR112015002526 B1 BR 112015002526B1
Authority
BR
Brazil
Prior art keywords
ester
process according
formula
mixture
solvent
Prior art date
Application number
BR112015002526-9A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112015002526A2 (pt
Inventor
Ruben Van Summeren
Harrie Vaessen
Daniel Mink
Mario Waser
Original Assignee
Basilea Pharmaceutica Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basilea Pharmaceutica Ag filed Critical Basilea Pharmaceutica Ag
Publication of BR112015002526A2 publication Critical patent/BR112015002526A2/pt
Publication of BR112015002526B1 publication Critical patent/BR112015002526B1/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Enzymes And Modification Thereof (AREA)
BR112015002526-9A 2012-08-07 2013-07-31 Derivado do (2r,3r)-éster do ácido 3-hidróxi-2-metil-4 [1,2,4]triazol-1-il-3-fenil-butírico, mistura de diastereoisômeros do referido éster e seu processo de fabricação BR112015002526B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12179540 2012-08-07
EP12179540.5 2012-08-07
PCT/EP2013/066071 WO2014023623A1 (en) 2012-08-07 2013-07-31 Process for the manufacture of isavuconazole or ravuconazole

Publications (2)

Publication Number Publication Date
BR112015002526A2 BR112015002526A2 (pt) 2018-06-12
BR112015002526B1 true BR112015002526B1 (pt) 2022-09-06

Family

ID=48979725

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015002526-9A BR112015002526B1 (pt) 2012-08-07 2013-07-31 Derivado do (2r,3r)-éster do ácido 3-hidróxi-2-metil-4 [1,2,4]triazol-1-il-3-fenil-butírico, mistura de diastereoisômeros do referido éster e seu processo de fabricação

Country Status (15)

Country Link
US (2) US9783508B2 (https=)
EP (1) EP2882723B1 (https=)
JP (1) JP6334529B2 (https=)
KR (1) KR102129150B1 (https=)
CN (1) CN104507917B (https=)
BR (1) BR112015002526B1 (https=)
CA (1) CA2878361C (https=)
ES (1) ES2616412T3 (https=)
HR (1) HRP20170171T1 (https=)
HU (1) HUE031679T2 (https=)
MX (1) MX360783B (https=)
PL (1) PL2882723T3 (https=)
PT (1) PT2882723T (https=)
SI (1) SI2882723T1 (https=)
WO (1) WO2014023623A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105801500B (zh) * 2014-12-31 2018-08-24 四川科伦药物研究院有限公司 拆分艾沙康唑中间化合物消旋体的方法
CN106317044A (zh) * 2015-06-30 2017-01-11 刘玫君 一种制造艾沙康唑或雷夫康唑的方法
CN104961695A (zh) * 2015-07-27 2015-10-07 成都塞恩斯医药科技有限公司 一种艾沙康唑和雷夫康唑中间体的制备方法
CN106467534B (zh) * 2015-08-17 2019-10-11 江苏奥赛康药业有限公司 一种硫酸艾沙康唑鎓化合物及其药物组合物
CN105907832B (zh) * 2015-12-02 2019-07-12 成都师范学院 一种酶法拆分艾沙康唑中间体的方法
CN108452848B (zh) * 2016-02-24 2020-12-11 上海兰立生物科技有限公司 一种催化剂
CA3061133A1 (en) 2017-04-27 2018-11-01 Codexis, Inc. Ketoreductase polypeptides and polynucleotides
WO2021245590A1 (en) * 2020-06-04 2021-12-09 Metrochem Api Private Limited An improved process for the preparation of triazole derivatives
CN111574444A (zh) * 2020-07-07 2020-08-25 安徽贝克生物制药有限公司 一种贝达喹啉的制备方法
CN116478103B (zh) * 2023-03-24 2025-07-25 四川澄华生物科技有限公司 一种拆分艾沙康唑中间体4的方法
CN119661453B (zh) * 2025-02-17 2025-04-22 四川澄华生物科技有限公司 一种制备艾沙康唑的主链中间体的方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8510195D0 (en) * 1985-04-22 1985-05-30 Ici Plc Heterocyclic compounds
US5134152A (en) 1989-12-07 1992-07-28 Sankyo Company, Limited Oxetane derivatives and their use as anti-fungal or fungicidal agents
JP2887523B2 (ja) * 1990-11-30 1999-04-26 富山化学工業株式会社 新規なトリアゾール誘導体およびその塩
GB9107055D0 (en) 1991-04-04 1991-05-22 Pfizer Ltd Triazole antifungal agents
JP4208269B2 (ja) * 1996-10-01 2009-01-14 東芝ソリューション株式会社 異種物混入検査方法及びそのシステム
AU7937998A (en) 1997-07-08 1999-02-08 Sankyo Company Limited Antifungal triazole compounds
AU2931399A (en) 1998-03-06 1999-09-20 F. Hoffmann-La Roche Ag 3-(4-(4-cyanophenyl)thiazol-2-y))-1-(1h-1,2,4-triazol-1-yl) -butan-2-ol derivatives having antifungal activity
PT1399402E (pt) * 2001-06-26 2010-11-30 Basilea Pharmaceutica Ag Derivados intermédios do grupo halofenilo e sua utilização em um processo para a preparação de derivados de azole
EP1954264B1 (en) 2005-12-01 2009-10-07 Basilea Pharmaceutica AG Process for the manufacture of epoxybutanol intermediates
GB0712972D0 (en) 2007-07-04 2007-08-15 Glaxosmithkline Consumer Healt Formulation
ES2652559T3 (es) 2007-07-04 2018-02-05 Dpx Holdings B.V. Preparación de una esterasa
CN102344457B (zh) 2007-09-12 2015-07-22 杏林制药株式会社 作为 gsk-3 抑制剂的螺环状氨基喹诺酮
NZ588983A (en) * 2008-06-25 2011-11-25 Daiichi Sankyo Co Ltd Carboxylic acid compound
WO2010001946A1 (ja) * 2008-07-03 2010-01-07 アステラス製薬株式会社 トリアゾール誘導体またはその塩
ES2689941T3 (es) 2009-04-24 2018-11-16 Patheon Austria Gmbh & Co Kg Esterasas de hígado de cerdo mejoradas
US8207352B2 (en) * 2009-10-08 2012-06-26 Drug Process Licensing Associates LLC Process for the manufacture of enantiomerically pure antifungal azoles as ravuconazole and isavuconazole
WO2011145669A1 (ja) * 2010-05-19 2011-11-24 大日本住友製薬株式会社 アミド誘導体

Also Published As

Publication number Publication date
BR112015002526A2 (pt) 2018-06-12
JP2015527345A (ja) 2015-09-17
CA2878361C (en) 2020-09-22
CN104507917A (zh) 2015-04-08
ES2616412T3 (es) 2017-06-13
HUE031679T2 (en) 2017-07-28
PL2882723T3 (pl) 2017-05-31
US20190077771A1 (en) 2019-03-14
KR20150037875A (ko) 2015-04-08
KR102129150B1 (ko) 2020-07-02
MX360783B (es) 2018-11-16
US9783508B2 (en) 2017-10-10
US20150239852A1 (en) 2015-08-27
EP2882723A1 (en) 2015-06-17
CN104507917B (zh) 2017-10-17
WO2014023623A1 (en) 2014-02-13
EP2882723B1 (en) 2016-11-16
JP6334529B2 (ja) 2018-05-30
CA2878361A1 (en) 2014-02-13
MX2015000744A (es) 2015-04-14
PT2882723T (pt) 2017-02-23
SI2882723T1 (sl) 2017-04-26
HRP20170171T1 (hr) 2017-04-07
US10590092B2 (en) 2020-03-17

Similar Documents

Publication Publication Date Title
BR112015002526B1 (pt) Derivado do (2r,3r)-éster do ácido 3-hidróxi-2-metil-4 [1,2,4]triazol-1-il-3-fenil-butírico, mistura de diastereoisômeros do referido éster e seu processo de fabricação
CN110951799B (zh) “一菌多酶”全细胞不对称合成(2s,3r)-对甲砜基苯丝氨酸的方法
US20100168433A1 (en) Process for preparing bepotastine and intermediates used therein
WO2016198660A1 (en) Transaminases
CN110343734B (zh) 一种l-草铵膦化学酶法生产方法
US20210284987A1 (en) Engineered polypeptides and their applications in the synthesis of beta-hydroxy-alpha-amino acids
JP6039710B2 (ja) L−アミノ酸の製造方法
KR101565439B1 (ko) 시타글립틴의 합성을 위한 전구체인 베타아미노산을 포함한 다양한 광학활성 베타아미노산의 효소적 생산 방법
US9890406B2 (en) Method for producing cathine
JP3140549B2 (ja) α−置換カルボン酸の光学異性体の分離法
WO2017092197A1 (zh) 一种艾沙康唑中间体的酶法拆分方法
KR101479717B1 (ko) 트랜스아미나제를 이용한 광학활성 알킬아민과 아릴알킬아민의 동시생산방법
JP2012193135A (ja) アミノ酸の製造方法
WO2006115194A1 (ja) 光学活性アミノ酸アミドの分離回収方法
JP5595400B2 (ja) 光学活性3−置換グルタル酸モノアミドの製造法
JP2006115726A (ja) 可溶化による光学活性β−ヒドロキシアミノ酸の製造方法
JPWO2008072764A1 (ja) 光学活性(r又はs)−ピペリジン−3−カルボン酸化合物及び光学活性(s又はr)−ピペリジン−3−カルボン酸アルキルエステル化合物の製造方法
JP2015139426A (ja) 新規β−アミノ酸の製造方法
JP2006121984A (ja) 鉱酸との混合による光学活性β−ヒドロキシアミノ酸の製造方法
KR20160096906A (ko) 라세믹 트레오닌으로부터 d-트레오닌 및 호모알라닌을 순차적으로 생산하는 방법
JP2013255505A (ja) 光学活性アミノ酸及びn−アルコキシカルボニルアミノ酸類の製造方法

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 31/07/2013, OBSERVADAS AS CONDICOES LEGAIS